Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Difficult-to-Treat Resistant Pseudomonas aeruginosa: Resistance Mechanisms and Susceptibility to the Novel Antipseudomonal β-Lactams.

Created on 07 Nov 2026

Authors

Yukihiro Kaneko, Hideki Kawamura, Koichi Yamada, Norihito Kaku, Katsunori Yanagihara

Published in

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. Pages 103120. Nov 06, 2026. Epub Nov 06, 2026.

Abstract

Pseudomonas aeruginosa is an intrinsically resistant, opportunistic Gram-negative pathogen and a major cause of healthcare-associated infection, with a marked ability to acquire further resistance during therapy. Multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) classifications are widely used but may poorly reflect treatment difficulty, since resistant isolates may remain susceptible to other effective agents. The difficult-to-treat resistance (DTR) framework identifies non-susceptibility to a clinically relevant set of first-line agents and provides a more treatment-focused phenotypic classification; it has been adopted by Infectious Diseases Society of America (IDSA) and by the new Japanese Society of Chemotherapy/Japanese Association for Infectious Diseases (JSC/JAID) guidance, although it remains underrecognized in Japan. Four novel antipseudomonal β-lactams are now available for DTR P. aeruginosa (DTR-P): ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, and cefiderocol. The 2026 JSC/JAID guidance incorporates underlying resistance mechanisms into its approach to selecting among these agents. This review examines the evidence linking individual resistance mechanisms to expected in vitro susceptibility, emphasizing the heterogeneity of DTR isolates and the importance of direct susceptibility testing. We also summarize current epidemiology in Japan, where carbapenemase-producing isolates remain uncommon and chromosomal mechanisms predominate, and contrast this with regional differences worldwide. We then examine the practical challenges of mechanism-based antimicrobial selection, including limited access to mechanism testing and the frequent coexistence of resistance mechanisms. Finally, we review clinical outcome evidence for the four agents, noting broadly comparable efficacy across available studies but limited direct comparative evidence and no prospective evidence establishing that mechanism-guided selection improves clinical outcomes over conventional approaches in DTR-P infections.

PMID:
42994690
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 31
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement